Drugs / GST-HG121
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT05576584 Comparator | Jul 2022 → Dec 2023 | — | Fujian Akeylink Biotechnology Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GST-HG121 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05576584 ↗ |
| Route | Oral | “gst-hg121 tablet or placebo was orally administered once under the fasting condition of D1” NCT05576584 ↗ |